May-June. 2026 | The HEALTH
CONTENTS
03
The HEALTH says...
Confidence in supply
05
P24 Beyond ' Data Cosplay ' People increasingly track biomarkers and longevity metrics while neglecting the foundational habits that truly determine longterm health.
P25 Rebuild, reinforce or replace? Factors such as age, bone quality, activity level, overall health and fracture complexity determine whether reconstruction, reinforcement or replacement is the most appropriate option.
06
P26-27 The language of food Essential nutrients such as protein, iron, zinc, iodine, and healthy fats help support cognitive development, memory, learning, and communication skills during the critical early years of childhood.
20-21
THE news that Malaysia’ s public healthcare system has sufficient pharmaceutical supplies for about six months is reassuring for healthcare workers and patients alike.
At a time when global conflicts are affecting trade and transport, alongside supply chain disruptions and economic uncertainty, having a strong supply of medicines is good news.
The COVID-19 pandemic taught the world an important lesson: countries cannot take access to medicines and medical supplies for granted. During the pandemic, many nations faced shortages as global supply chains struggled to meet high demand. Malaysia also experienced some of these challenges. This is why Pharmaniaga’ s decision to increase its buffer stock and place orders earlier than usual is a positive step. By planning ahead, the company is helping to reduce the risk of shortages should global supply chains face further disruptions.
Under its agreement with the Ministry of Health, Pharmaniaga maintains a two-month stock buffer, suppliers hold another two months, and hospitals keep a further two months of supply. Together, this creates a six-month safety net for the public healthcare system.
This level of preparedness is important. Global events, such as the ongoing conflict in the Middle East, can disrupt the movement of goods, including medicines and the raw materials used to produce them.
Maintaining extra stock gives Malaysia valuable time to respond if supply problems arise.
While the current stockpile provides reassurance, it is only a temporary measure to manage short-term risks. It does not fully protect the country from longterm supply disruptions or rising costs.
The healthcare sector has already been warned that higher prices for pharmaceutical products and raw materials may become more apparent later this year. This could occur as suppliers deplete inventories purchased at lower prices. If global uncertainty persists, healthcare providers may face rising costs in the months ahead.
This highlights the need for Malaysia to strengthen its pharmaceutical sector over the long term. One way to do this is to expand local manufacturing.
Producing more medicines and pharmaceutical ingredients domestically could reduce reliance on overseas suppliers and make the healthcare system more resilient.
At the same time, close cooperation among the government, healthcare providers and industry players remains essential.
Pharmaniaga’ s decision to establish a special task force to monitor supply and pricing exemplifies the proactive approach required in today’ s uncertain environment.
For now, Malaysians can take comfort in knowing that essential medicines remain accessible within the public healthcare system.
But the focus should not be only on the stock available today. The bigger challenge is ensuring the country can continue to provide affordable and reliable access to medicines in the future.